The FDA has approved tucatinib (TUKYSA) in combination with trastuzumab and pertuzumab as first-line maintenance treatment for adults with HER2-positive metastatic breast cancer based on the Phase 3 HER2CLIMB-05 trial. Erika Hamilton, MD, presented the trial results at #SABCS25.

Camizestrant received accelerated FDA approval Friday. At #SABCS25, François-Clément Bidard, MD, presented updated Phase 3 SERENA-6 results showing how ctDNA can detect treatment resistance before disease progression. What will we see next? Join us at #SABCS26, Dec. 8–11. https://bit.ly/463weSl